secwatch.observer — SEC 8-K summary
======================================

Issuer:     Athenex, Inc. (—)
CIK:        0001300699
Form:       8-K
Filed at:   2023-07-18T23:59:59+00:00
Accession:  0001193125-23-188536
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 1.02, 1.03, 2.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Athenex sells Orascovery assets for $2.5M + milestone, APD assets for $14M amid Chapter 11
--------------------------------------------------------------------------------

- Health Hope Pharma (C-Mer assignee) bought Orascovery assets for $2.5M cash plus $5M milestone on oral paclitaxel sales.
- Sagent Pharmaceuticals purchased APD assets for ~$14M; Oaktree credit-bid $20M for APD cash and receivables.
- Settlement with Almirall, Sagard, Oaktree: Almirall buys tirbanibulin inventory up to $2.44M; Sagard releases $3.5M escrow.
- CEO Jeffrey Yordon and CFO Daniel Lang terminated June 30, 2023; Lang retained as consultant at $210/hour through July 31.
- Company cautions common stock trading is highly speculative during bankruptcy; recovery for shareholders uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1300699/000119312523188536/0001193125-23-188536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1300699/000119312523188536/d520119d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-188536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer